Business
HitGen Receives New Funding to Discover Novel Therapeutics for Underserved Diseases
Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), today announced that it has entered into a new contract agreement with the Gates Foundation. HitGen will leverage its industry-leading DNA-encoded library (DEL) platform to identify novel drug leads for the treatment of underserved diseases including tuberculosis and malaria, as well as to discover novel agents for non-hormonal contraception.
About this update from Hitgen Inc. Class A
[{"type":"list","items":[{"val":[{"type":"text","content":"Company enters into new agreement with the Gates Foundation to identify novel drug leads targeting tuberculosis and malaria and new agents for non-hormonal contraception.","length":170,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":170,"olType":false},{"type":"text","content":"CHENGDU, China, Nov. 20, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), today announced that it has entered into a new contract agreement with the Gates Foundation. HitGen will leverage its industry-leading DNA-encoded library (DEL) platform to identify novel drug leads for the treatment of underserved diseases including tuberculosis and malaria, as well as to discover novel agents for non-hormonal contraception.","length":479,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/HitGen Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/HitGen Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":141,"url":"https://media.zenfs.com/en/prnewswire.com/2f3813f861dc7c412908f15da9664a3b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i.0s4PPSHzT.nmBc2ShuxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI0OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2f3813f861dc7c412908f15da9664a3b","width":400,"height":141}},"href":"https://mma.prnewswire.com/media/2758868/HitGen_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the terms of the agreement, HitGen will conduct DEL screening against 15 drug targets identified by the Gates Foundation in cooperation with its partners in academia and research institutes. HitGen will receive funding for the discovery work from the Gates Foundation, building upon a previous project supported by the foundation under which HitGen identified novel drug leads for the treatment of malaria and tuberculosis.","length":429,"tagName":"p"},{"type":"text","content":""We are honored to continue this important work with support from the Gates Foundation," said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen Inc. "We look forward to engaging with other world-leading philanthropic and academic institutions to deliver transformative solutions for patients with unmet medical needs."","length":365,"tagName":"p"},...